Literature DB >> 8148489

Biology of factor IX.

K Kurachi1, S Kurachi, M Furukawa, S N Yao.   

Abstract

Within the past 20 years or so, factor IX has been at the centre of particularly intensive studies of its physiology, pathology and biochemistry as well as its molecular genetics and biology. With the complete nucleotide sequence of its human gene determined in 1985 and the molecular defects of over 600 abnormal human factor IX genes analysed to date, factor IX is among the few mammalian proteins which have been exhaustively studied in almost every aspect. The enormous amount of information we now have on this medium-sized plasma protein sheds light on how a gene and its protein evolve, how the protein carries out a highly regulated, specific and pivotal role in the delicately balanced blood coagulation reaction, and the correlation between clinical presentations and its highly diverse molecular mechanism of defects. This wealth of knowledge makes factor IX an excellent model for deeper study, such as truly quantitative analysis of its structure-function relationship and in vivo function and regulation. It will also provide a sound foundation which may lead to improved treatment of haemophilia B and perhaps to its cure. This paper attempts to review the recent progress in research on factor IX.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8148489

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  5 in total

1.  Kinetics of recombinant adeno-associated virus-mediated gene transfer.

Authors:  A K Malik; P E Monahan; D L Allen; B G Chen; R J Samulski; K Kurachi
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B.

Authors:  H Brandstetter; M Bauer; R Huber; P Lollar; W Bode
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

3.  Treatment of hemophilia B: focus on recombinant factor IX.

Authors:  Massimo Franchini; Francesco Frattini; Silvia Crestani; Cinzia Sissa; Carlo Bonfanti
Journal:  Biologics       Date:  2013-02-12

4.  Engineering protein processing of the mammary gland to produce abundant hemophilia B therapy in milk.

Authors:  Jianguo Zhao; Weijie Xu; Jason W Ross; Eric M Walters; Stephen P Butler; Jeff J Whyte; Lindsey Kelso; Mostafa Fatemi; Nicholas C Vanderslice; Keith Giroux; Lee D Spate; Melissa S Samuel; Cliff N Murphy; Kevin D Wells; Nick C Masiello; Randall S Prather; William H Velander
Journal:  Sci Rep       Date:  2015-09-21       Impact factor: 4.379

5.  Characterization of IXINITY® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph.

Authors:  Dougald M Monroe; Richard J Jenny; Kevin E Van Cott; Shelly Buhay; Laura L Saward
Journal:  Adv Hematol       Date:  2016-02-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.